No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.

Related Articles No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 Jun 21;: Authors: Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ Abstract OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and…

Read More

Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD.

Related Articles Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol. 2018 Jun 21;: Authors: Targownik LE, Leung S, Lix LM, Singh H, Bernstein CN Abstract OBJECTIVES: Immunomodulator (IM)-based monotherapy with thiopurines or methotrexate is being increasingly supplanted in the management of moderate-to-severe IBD by more efficacious biologic agents. However, given their low cost, IMs may still have a selective role in this setting. METHODS: We used a Canadian population-based dataset of persons with IBD spanning from 1996 until…

Read More

Wheat Intolerance and Chronic Gastrointestinal Symptoms in an Australian Population-based Study: Association Between Wheat Sensitivity, Celiac Disease and Functional Gastrointestinal Disorders.

Related Articles Wheat Intolerance and Chronic Gastrointestinal Symptoms in an Australian Population-based Study: Association Between Wheat Sensitivity, Celiac Disease and Functional Gastrointestinal Disorders. Am J Gastroenterol. 2018 Jun 19;: Authors: Potter MDE, Walker MM, Jones MP, Koloski NA, Keely S, Talley NJ Abstract OBJECTIVES: Wheat avoidance in the absence of celiac disease (CD) is common but occurrence of concurrent functional gastrointestinal disorders (FGIDs) in this group is uncertain. The aims of this study were to determine the prevalence of self-reported wheat or gluten sensitivity and doctor diagnosed CD in an…

Read More

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?

Related Articles Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Am J Gastroenterol. 2018 Jun 19;: Authors: Koretz RL Abstract Probiotic usage has become popular with both medical practitioners and the community in general; patients commonly seek advice regarding what, if any, such preparation would be useful for their own diseases. Since such advice should be evidence-based, identified randomized clinical trials (RCTs) for a number of gastrointestinal conditions were reviewed; the data were organized by individual probiotic genera/species. Only trials in adults were considered. Most of the identified…

Read More

Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults.

Related Articles Correction: ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018 Jun 12;: Authors: Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE Abstract Since the publication of these Guidelines, the authors have noticed an error in the text on page 15. The incorrect statement is. PMID: 29895986 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29895986?dopt=Abstract

Read More

The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation.

Related Articles The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation. Am J Gastroenterol. 2018 Jun 12;: Authors: Nhu QM, Chiao H, Moawad FJ, Bao F, Konijeti GG PMID: 29895980 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29895980?dopt=Abstract

Read More

Beyond O&P Times Three.

Related Articles Beyond O&P Times Three. Am J Gastroenterol. 2018 Jun 05;: Authors: Mohapatra S, Singh DP, Alcid D, Pitchumoni CS Abstract Although examination of the stool for ova and parasites times three (O&P ×3) is routinely performed in the United States (US) for the evaluation of persistent and/or chronic diarrhea, the result is almost always negative. This has contributed to the perception that parasitic diseases are nearly non-existent in the country unless there is a history of travel to an endemic area. The increasing number of immigrants from third-world…

Read More

Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials.

Related Articles Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018 Jun 05;: Authors: Singh S, Proudfoot J, Xu R, Sandborn WJ Abstract OBJECTIVES: To assess whether obesity may affect response to infliximab, we conducted an individual participant data pooled analysis using data from clinical trials of infliximab in inflammatory bowel diseases (IBD), using the Yale Open Data Access (YODA) Project. METHODS: We analyzed individual participant data from four clinical trials of infliximab in adults…

Read More
<< Go Back